KPC-33 and ompK37 mutations: Unraveling the mechanism of ceftazidime/avibactam resistance in ST11 carbapenem-resistant Klebsiella pneumoniae.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 41770798.
- Also identified by DOI 10.1371/journal.pone.0342729 and PMC identifier 12952571.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Global surveillance indicates rising ceftazidime-avibactam resistance among carbapenem-resistant Klebsiella pneumoniae (CRKP), with sequence type 11 predominating in China. The contribution of blaKPC variants and porin alterations to high-level resistance remains significant. We employed whole-genome sequencing and functional analyses to characterise a CZA-resistant ST11 CRKP isolate recovered from a patient without prior exposure to ceftazidime-avibactam or carbapenems. The isolate harboured blaKPC-33 on a non-conjugative plasmid and multiple non-synonymous mutations in the porin gene ompK37, concomitant with high-level resistance to ceftazidime-avibactam and carbapenems while retaining susceptibility to tigecycline, polymyxin B and amikacin. blaKPC-33 coupled with OmpK37 alterations underpins dual resistance to ceftazidime-avibactam and carbapenems in ST11 CRKP, underscoring the need for genomic surveillance and rapid detection of this resistance mechanism.
Medical subject headings
- Ceftazidime
- Klebsiella pneumoniae
- Azabicyclo Compounds
- Carbapenems
- Mutation
- Porins
- beta-Lactamases
- Bacterial Proteins
- Drug Resistance, Multiple, Bacterial